Date | Title | Description | Source |
13.03.2024 | Mesoblast Successfully Completes Placement and Accelerated E... | - | globenewsw... |
10.03.2024 | United States Food & Drug Administration (FDA) Supports ... | NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader... | einpresswi... |
28.02.2024 | Mesoblast Reports Financial Results and Operational Update f... | NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | einpresswi... |
26.11.2023 | Mesoblast Files for Orphan Drug and Pediatric Rare Disease D... | NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | einpresswi... |
21.11.2023 | Mesoblast Partners With Blood and Marrow Transplant Clinical... | NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | einpresswi... |
05.06.2023 | Mesoblast Director Philip R. Krause, M.D., Appointed to Stra... | /EIN News/ -- NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), ... | einpresswi... |
24.05.2023 | Mesoblast Financial Results and Corporate Update Webcast | /EIN News/ -- NEW YORK, May 24, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), g... | einpresswi... |
22.03.2023 | FDA Schedules Pre-License Inspection of Remestemcel-L Manufa... | /EIN News/ -- Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host... | einpresswi... |
08.03.2023 | FDA Accepts Mesoblast’s Resubmission of the Biologic License... | If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US,... | einpresswi... |
31.01.2023 | Appendix 4C Quarterly Activity Report | Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022
/EIN News/ -- NEW... | einpresswi... |
23.12.2022 | Mesoblast and Oaktree Extend Availability Period of Undrawn ... | /EIN News/ -- NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), ... | einpresswi... |
21.11.2022 | Mesoblast Financial Results and Corporate Update Webcast | /EIN News/ -- NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), ... | einpresswi... |
30.10.2022 | Mesoblast Operational and Financial Highlights for Quarter E... | NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
02.10.2022 | Mesoblast Submits New Information to FDA IND File in Respons... | NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
30.08.2022 | Mesoblast Reports Financial Results and Operational Highligh... | At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gro... | globenewsw... |
29.08.2022 | Mesoblast Corporate Update and Financial Results Webcast | NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader ... | globenewsw... |
18.08.2022 | Jane Bell Joins Mesoblast Board | NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
29.07.2022 | Appendix 4C Quarterly Activity Report | NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
11.07.2022 | Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-... | NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
09.06.2022 | Mesoblast Key Opinion Leader Event Series for Investors &... | NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
31.05.2022 | Operational Highlights and Financial Results for the Period ... | NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in... | globenewsw... |
28.04.2022 | Appendix 4C Quarterly Activity Report | NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader... | globenewsw... |
23.03.2022 | Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines... | NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader... | globenewsw... |
24.02.2022 | Operational Highlights and Financial Results for the Period ... | NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
20.02.2022 | Rapid Improvement and Remission in Patients With Refractory ... | NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
01.02.2022 | Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer | NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader i... | globenewsw... |
30.01.2022 | Appendix 4C Quarterly Activity Report | NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
22.01.2022 | Mesoblast : Management Team | Management Team
Mesoblast has a highly experienced management team made up of individuals who have h... | marketscre... |
12.01.2022 | Single Dose of Mesoblast's Allogeneic Cell Therapy Provides ... | 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase
NEW YO... | marketscre... |
12.01.2022 | Single Dose of Mesoblast's Allogeneic Cell Therapy Provides ... | NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | marketscre... |
11.01.2022 | Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides ... | NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
30.12.2021 | Mesoblast Provides Update Following Meeting With FDA’s OTAT ... | Key Points:
Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Adva... | globenewsw... |
15.12.2021 | FDA’s OTAT in Agreement With 12-Month Reduction in Pain as P... | NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
13.12.2021 | Update on Novartis Agreement | NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
05.12.2021 | Rexlemestrocel-L Shows Greatest Treatment Benefit on Major A... | Key points:
Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestroc... | globenewsw... |
24.11.2021 | Mesoblast : MSB Q1 Financial Results and Operational Highlig... | For personal use only
OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE PERIOD ENDED
SEPTEMBER 30... | marketscre... |
24.11.2021 | Operational Highlights and Financial Results for the Period ... | NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | marketscre... |
23.11.2021 | Operational Highlights and Financial Results for the Period ... | NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
23.11.2021 | Mesoblast Corporate Update and Financial Results Webcast | NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
22.11.2021 | Mesoblast and Oaktree Capital Enter Into Refinancing and Exp... | NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | marketscre... |
21.11.2021 | Mesoblast and Oaktree Capital Enter Into Refinancing and Exp... | NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
14.11.2021 | Late Breaking Presentation at American Heart Association Ann... | Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Gre... | globenewsw... |
09.11.2021 | Corporate Governance Council Principles and Recommendations ... | Corporate Governance Council Principles and Recommendations
Name of entity
Mesoblast Limited
ABN/ARB... | marketscre... |
28.10.2021 | Appendix 4C Quarterly Activity Report | NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
18.10.2021 | Remestemcel-L Improves Survival of Children With Biomarkers ... | NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
06.10.2021 | Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Fail... | NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
02.10.2021 | Mesoblast : Management Team | Management Team
Mesoblast has a highly experienced management team made up of individuals who have h... | marketscre... |
31.08.2021 | Operational Highlights and Financial Results for the Year En... | NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | marketscre... |
28.08.2021 | Mesoblast : Management Team | Management Team
Mesoblast has a highly experienced management team made up of individuals who have h... | marketscre... |
19.07.2021 | Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remes... | NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | marketscre... |
03.06.2021 | Operational Highlights and Financial Results for the Period ... | NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | marketscre... |
30.04.2021 | Appendix 4C Quarterly Activity Report | NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader... | marketscre... |
30.04.2021 | Remestemcel-L Reduces Mortality in Patients Less Than 65 Yea... | Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old
I... | marketscre... |
10.03.2021 | MESOBLAST LIMITED
Mesoblast Limited : - MSB Closes US$110M ... | Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in allogeneic cellular medicines for infla... | marketscre... |
09.03.2021 | MESOBLAST LIMITED
Mesoblast Closes US$110/A$138 Million Fin... | NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader... | marketscre... |
09.03.2021 | MESOBLAST LIMITED
Mesoblast : MSB Closes US$110M Raise Led ... | MESOBLAST CLOSES US$110/A$138 MILLION FINANCING LED BY US STRATEGIC
INVESTOR GROUP
Melbourne, Austra... | marketscre... |
08.03.2021 | Mesoblast Closes US$110/A$138 Million Financing Led by US St... | NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader... | globenewsw... |
02.03.2021 | Mesoblast gets a $110M lifeline from SurgCenter Develop... | Mesoblast faced rough waters in 2020, but on Monday were thrown a financial lifeline.
The Aust... | endpts.com... |
02.03.2021 | Mesoblast Completes US$110/A$138 Million Financing Led by US... | NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced toda... | globenewsw... |
23.02.2021 | Candid Conversations with World-Leading Startup Ecosystem Le... | Kate Cornick, CEO of LaunchVic was interviewed by JF Gauthier, Founder & CEO of Startup Genome, ... | startupgen... |
10.02.2021 | Mesoblast Phase 3 Trial Shows That a Single Injection of Rex... | NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
10.02.2021 | Mesoblast Corporate Update | NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ... | globenewsw... |
03.12.2020 | Mesoblast : 2020 Annual Report | ANNUAL REPORT 2020
GLOBAL LEADER
IN ALLOGENEIC CELLULAR MEDICINES FOR INFLAMMATORY DISEASES
CONTENTS... | marketscre... |
03.12.2020 | MESOBLAST LIMITED
Mesoblast : 2020 Annual Report | ANNUAL REPORT 2020
GLOBAL LEADER
IN ALLOGENEIC CELLULAR MEDICINES FOR INFLAMMATORY DISEASES
CONTENTS... | marketscre... |
28.05.2020 | MESOBLAST LIMITED
Mesoblast : MSB Reports Q3 Financial Resu... | o 15% decrease in research and development spend (US$40.9 million compared with US$48.4 million)
• C... | marketscre... |
17.02.2017 | Nine months of rheumatoid arthritis suppression with one ste... | While much larger Phase 3 studies are needed to validate the results, the data offer a tantalizing l... | medcitynew... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
14.03.2013 | Mesoblast raises $175M for PhIII stem cell study | Mesoblast CEO Silviu Itescu
Australia's regenerative medicines company Mesoblast (ASX: MSB) reports ... | fiercebiot... |
- | Mesoblast Limited : - MSB Closes US$110M Raise Led By US Str... | Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in allogeneic cellular medicines for infla... | marketscre... |
- | Nine months of rheumatoid arthritis suppression with one ste... | Dividing mesenchymal stem cells
It’s the kind of the data the field has worked towards for years.
Rh... | medcitynew... |
- | Mesoblast : MSB Closes US$110M Raise Led By US Strategic Inv... | MESOBLAST CLOSES US$110/A$138 MILLION FINANCING LED BY US STRATEGIC
INVESTOR GROUP
Melbourne, Austra... | marketscre... |